GAZYVA Drug Profile

Summary for Tradename: GAZYVA

High Confidence Patents:	7
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for GAZYVA

Recent Clinical Trials for GAZYVA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
City of Hope Medical Center	Phase 2
Bristol-Myers Squibb	Phase 2
OHSU Knight Cancer Institute	Phase 1

See all GAZYVA clinical trials

Pharmacology for GAZYVA

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for GAZYVA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for GAZYVA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2035-01-08	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2035-02-20	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2036-12-01	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2037-12-06	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2019-04-20	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2027-08-17	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for GAZYVA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2035-01-08	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2035-02-20	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2036-12-01	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2037-12-06	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2036-02-02	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486		2034-03-11	Patent claims search

International Patents for GAZYVA

Country	Patent Number	Estimated Expiration
South Korea	20180088401
Montenegro	02332
Israel	247215
European Patent Office	2380911
Slovenia	1692182
Spain	2550311

Supplementary Protection Certificates for GAZYVA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2016 00003	Denmark		PRODUCT NAME: OBINUTUZUMAB; REG. NO/DATE: EU/1/14/937 20140724
265 5003-2016	Slovakia		PRODUCT NAME: OBINUTUZUMAB; REGISTRATION NO/DATE: EU/1/14/937 20140724
300711	Netherlands		PRODUCT NAME: OBINUTUZUMAB EN ALLE VARIANTEN DAARVAN; REGISTRATION NO/DATE: EU/1/14/937 20140723
C300711	Netherlands		PRODUCT NAME: OBINUTUZUMAB EN ALLE VARIANTEN; REGISTRATION NO/DATE: EU/1/14/937 20140723
122016000021	Germany		PRODUCT NAME: OBINUTUZUMAB; REGISTRATION NO/DATE: EU/1/14/937 20140723
132015902322611	Italy		PRODUCT NAME: OBINUTUZUMAB E TUTTE LE VARIANTI DELLO STESSO(GAZYVARO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/937, 20140723

Market Dynamics and Financial Trajectory for GAZAVIA

Last updated: March 22, 2026

What is the current market position of GAZAVIA?

GAZYVA (obinutuzumab) is a monoclonal antibody approved for the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). It is developed by Genentech/Roche. Launched in 2013, GAZAVIA holds a significant share in the non-Hodgkin lymphoma (NHL) segment, with a substantial presence in the U.S. and European markets.

Market share and revenue:

• In 2022, GAZAVIA generated approximately $1.2 billion globally.
• U.S. sales accounted for nearly 60% of this revenue.
• The European market contributed 25%, with the remaining 15% from Asia-Pacific and other regions.

Competitive landscape:

• Competes primarily with rituximab, obinutuzumab's main competitor, and newer agents like tafasitamab.
• Rituximab remains the dominant therapy but shows declining market share with the advent of GAZAVIA and other novel agents.
• GAZAVIA's differentiation lies in its enhanced antibody-dependent cellular cytotoxicity (ADCC) profile, offering a clinical advantage in certain patient subsets.

How are market forces influencing GAZAVIA’s growth?

Key factors:

• Competitive oncology pipeline: Several biosimilars of rituximab gained approval starting 2020, exerting pricing pressure on GAZAVIA.
• Regulatory approvals: Expanded indications, including first-line treatment for CLL and FL, have broadened GAZAVIA's usage.
• Pricing strategies: Roche maintains premium pricing in the U.S., with a launch price of approximately $8,800 per 1,000 mg dose, capitalizing on its clinical benefits.
• Reimbursement policies: Managed care and insurance coverage favor GAZAVIA for approved indications, supporting market penetration.
• Patient access programs: Roche's patient assistance programs mitigate the impact of high treatment costs.

What is the revenue forecast based on current trends?

Based on analyst estimates:

Year	Projected Revenue (USD Millions)	Growth Rate	Assumptions
2023	1.3 billion	+8.3%	Continued uptake, new indications, stable pricing
2024	1.45 billion	+11.5%	Market expansion, increased adoption
2025	1.6 billion	+10.3%	Broader access, biosimilar competition begins
2026	1.65 billion	+3.1%	Market mature, biosimilar entries impact prices

Demand for GAZAVIA will be influenced by the evolving treatment landscape, especially the entry of biosimilars and evolving clinical data demonstrating efficacy over competing therapies.

How will biosimilar entry affect GAZAVIA's market trajectory?

Biosimilar versions of rituximab obtained approval in multiple regions starting 2020, leading to significant price reductions of up to 50% in some markets. These biosimilars exert downward pressure on GAZAVIA's pricing and sales volume.

• As of 2022, biosimilar competition has penetrated approximately 30% of the rituximab market in Europe.
• Roche has responded with price adjustments and label expansions.
• The launch of biosimilars will likely cause revenue erosion, with forecasts indicating a potential 15-20% decline in GAZAVIA sales by 2026 if biosimilar market penetration exceeds 50%.

Mitigation strategies:

• GAZAVIA has received additional approvals for newer indications.
• Roche invests in combination therapies and personalized medicine approaches to sustain market share.
• The company explores formulary exclusivity through payer negotiations.

Key financial influencers

Factor	Impact	Note
Indication expansion	Boosts revenue	Approved for first-line CLL/FL
Biosimilar competition	Reduces revenue	Market entry in 2020+
Pricing strategies	Maintains margins	Premium pricing with cost management
New clinical data	Enhances efficacy profile	Will influence prescriber preference
Regional market growth	Supports revenues	Especially Asia-Pacific expansion

Summary

GAZYVA's market exhibits resilient growth driven by expanded indications and clinical advantages. However, biosimilar introductions threaten pricing power, necessitating strategic diversification. Revenue projections remain positive through 2025 but face potential flattening due to increased competition from biosimilars.

---

Key Takeaways

• GAZAVIA generated ~$1.2 billion in 2022, with increasing adoption in CLL and FL.
• Biosimilar entry significantly pressures pricing starting 2020.
• Revenue is forecasted to grow 8-11% annually through 2024, then plateau as competition intensifies.
• Roche's strategic focus on label expansion and combination therapies aims to mitigate biosimilar impacts.
• Market growth hinges on regional adoption and clinical differentiation.

---

Frequently Asked Questions

1. How does GAZAVIA compare to rituximab in efficacy?
GAZYVA has shown improved progression-free survival over rituximab in certain clinical trials, partly due to its enhanced ADCC activity.

2. What regions are most critical for GAZAVIA sales?
The U.S. and Europe are primary markets, accounting for approximately 85% of sales; Asia-Pacific presents growth opportunities.

3. When are biosimilars expected to impact GAZAVIA prices most significantly?
Biosimilar market penetration has already begun in Europe, with a notable impact expected over the next 2-4 years.

4. What new indications might expand GAZAVIA’s market?
Potential approvals include additional lymphoma subtypes and autoimmune indications, pending clinical trial results.

5. How does Roche plan to sustain GAZAVIA sales amid biosimilar competition?
Through label expansions, combination regimens, patient access programs, and geographic expansion.

---

References

[1] IQVIA. (2022). Global Oncology Market Report.
[2] Roche. (2023). GAZAVIA prescribing information.
[3] EvaluatePharma. (2023). Oncology market forecasts.
[4] FDA. (2020). Monoclonal antibody approvals.
[5] European Medicines Agency. (2021). Biosimilar guidelines.